• to lessen the risk of severe cardiovascular (coronary heart and blood vessel) challenges in Older people with type 2 diabetes and cardiovascular diseaseCalifornia biotech behemoth Amgen ditched designs for an experimental weight loss tablet in May but continues to be hoping for a slice of the market with MariTide, a month to month injection tha